Analytical Testing Before an IND Submission

For early-stage biotech teams preparing their first Investigational New Drug application, the CMC analytical testing requirements in the Chemistry, Manufacturing, and Controls section are often where timelines stall.

FDA does not require commercial-grade data at the IND stage, but it does expect sufficient analytical characterization to demonstrate that your drug substance and drug product are consistently manufactured and safe to administer in clinical trials. Working with a qualified analytical testing laboratory from the outset gives teams the infrastructure to generate that data without building it from scratch.

The scope of required testing depends on the proposed clinical phase, route of administration, and molecular complexity — but the core categories are consistent across most programs.

Key Takeaways

Identity, purity, and potency are baseline requirements.

Microbiology requirements scale with the administration route.

Early stability data must support proposed storage conditions through the clinical trial period.

Elemental impurity and extractables assessments belong in the early planning phase.

Externally generated cGMP data is well-accepted by FDA.

Drug Substance Characterization: What FDA Expects Before Phase 1

Before IND submission, FDA requires enough characterization of the drug substance to define its identity, strength, quality, and purity.

Small Molecules

For small molecules, required characterization typically includes:

Structural confirmation via NMR, MS, and IR
Appearance and physical form data
Assay by a qualified HPLC method
Impurity profile covering process-related impurities (residual solvents, reagents) and degradation products

Biologics and Advanced Modalities

For monoclonal antibodies, proteins, and newer modalities such as mRNA therapeutics, characterization requirements are broader. Testing typically expected before Phase 1 begins includes:

Host cell protein residuals and residual DNA
Aggregation by SEC-HPLC
Potency via binding or functional assay
Identity by peptide mapping or electrophoretic methods

A typical mAb IND analytical package spans 15–25 assays across release, characterization, and nonclinical bioanalysis.

Nitrosamines

Nitrosamines have become an additional pre-IND consideration following FDA and EMA guidance beginning in 2019. Where the synthetic route or raw materials present a risk of nitrosamine formation, a risk assessment — and potentially confirmatory testing by GC-MS/MS or LC-MS/MS — should be completed before submission. (See the nitrosamines testing overview for a full breakdown of detection capabilities across NDMA, NDEA, and NDSRIs).

Drug Product Testing: Release Requirements for Clinical Batches

The CMC section requires lot release-equivalent data from the batches used in Phase 1 trials. Specifications at IND do not need to mirror commercial release criteria, but they must be scientifically justified and consistent across batches.

Sterile Dosage Forms

Sterile product release testing typically includes:

Sterility testing
Bacterial endotoxin testing (BET/LAL)
Particulate matter per USP <788> or <789>
Container closure integrity
Appearance, pH, assay, and degradation products

Non-Sterile and Inhalation Products

Oral solids: dissolution or disintegration data, content uniformity per USP <905>, impurity profile
Inhalation products (MDIs, DPIs, nebulizers): aerodynamic particle size distribution via cascade impaction, delivered dose uniformity

Stability Data for IND Submissions: Minimum Requirements and Common Gaps

FDA guidance (21 CFR 312.23 and supporting guidances) requires stability data to support the proposed storage conditions and expiry dating through the trial period.

What the Data Package Needs to Cover

Accelerated stability data, typically three to six months
At least the first real-time time point under ICH Q1A long-term conditions
A stability-indicating method demonstrated to detect degradation via forced degradation studies
Photostability per ICH Q1B, depending on the container and labeling

Stability chambers need to be running well before the IND is filed. Programs that wait until the clinical batch is manufactured consistently run into submission delays — there is no shortcut around real-time data requirements.

Environmental Monitoring and Safety Testing

What Reviewers Look For

Microbiological control of the manufacturing environment is documented through environmental monitoring data submitted with batch records in the IND. Reviewers look for evidence of adequate facility control, including:

Viable and non-viable particulate air sampling
Surface and personnel monitoring
Water system testing

Extractables Assessments

For parenteral and inhalation products, an extractables risk assessment of the primary container and any single-use manufacturing components is advisable even at Phase 1. The applicable frameworks are USP <661> for container closure systems and ISO 10993 for medical device combination products. The requirement depends on risk factors including route of administration, container closure composition, and duration of contact.

Choosing a cGMP Contract Testing Laboratory for IND Work

Why Most Early-Stage Programs Outsource

Early-stage biopharmaceutical and pharmaceutical companies rarely have the in-house analytical infrastructure to execute IND-enabling testing across all required categories. Building out cGMP analytical labs, hiring qualified staff, validating methods, and establishing quality systems requires significant time and capital. Few programs can justify it before proof-of-concept data exists.

According to the IQVIA Institute 2025 Global Trends in R&D Report, emerging biopharma companies now account for 63% of clinical trial starts globally, up from 56% in 2019 — the majority pre-commercial and without the in-house resources or analytical infrastructure to develop an asset through commercialization. For these sponsors, outsourcing is the operating model.

What to Look for When Evaluating Your Options

Contract testing laboratories operating under cGMP — with FDA/DEA registration and accreditations such as ISO/IEC 17025:2017 — provide established, auditable infrastructure that regulators accept. The selection criteria that matter most:

Scientific depth across all required service categories
Method development and validation capability, not just routine testing
Familiarity with FDA expectations at the IND stage
A quality system built to withstand inspection

Why Full-Service Matters for CMC Coherence

A full-service cGMP contract testing laboratory can carry an early-stage program from characterization through release testing, stability, and environmental monitoring under a single quality agreement, with consistent documentation standards across all assays. The CMC section must present a coherent picture of manufacturing and quality control. Fragmented testing across multiple labs with different LIMS platforms, SOPs, and reporting formats creates inconsistencies that reviewers notice.

Frequently Asked Questions

Does FDA require validated methods for an IND submission?

At Phase 1, methods must be qualified — sufficient to demonstrate fitness for purpose — but full ICH Q2(R1) validation is not required until later development stages. The appropriate qualification level should be commensurate with the criticality of the test and the stage of the program.

How many stability time points are needed before filing an IND?

There is no fixed requirement, but FDA generally expects data sufficient to project stability through the Phase 1 trial period, typically supported by accelerated data and at least one real-time time point. The specific package should be discussed with your regulatory team early in planning.

Can a CRO generate sterility and endotoxin data used in an IND?

Yes — FDA accepts externally generated cGMP data provided the testing laboratory operates under an appropriate quality agreement and can demonstrate compliance during audit or inspection.

What distinguishes a drug substance specification from a drug product specification at IND?

Drug substance specifications address the API — identity, assay, impurities, and physical properties. Drug product specifications cover those same attributes plus dosage-form-specific release tests such as dissolution, sterility, and container integrity.

Are extractables studies required for all drug products at IND?

The requirement depends on risk factors including route of administration, container closure composition, and duration of contact. Parenteral and inhalation products face the greatest scrutiny; an extractables risk assessment is advisable for any high-risk combination even if a full leachables study is not yet complete.

Ready to Build Your IND Testing Package?

BA Sciences supports early-stage pharmaceutical and biotech programs with the full range of analytical, microbiology, stability, and safety testing required for IND submissions — across small molecules, biologics, and advanced therapeutics. Request a quote to discuss your program.

What Analytical Testing Do You Need Before an IND Submission?